Exploring the Moroccan Pharmaceutical Landscape
The Moroccan pharmaceutical market presents a significant opportunity for foreign investment, particularly from German companies. Despite Germany's pharmaceutical industry having a modest share of less than 10 percent in Morocco, the market is exhibiting promising growth. Statistics from the HCP indicate that the pharmaceutical market volume reached 27.8 billion Dirhams (approximately 2.75 billion Euros) in 2025, up from 25.9 billion Dirhams (about 2.5 billion Euros) the previous year. This growth can be attributed to the expansion of mandatory health insurance and rising per capita spending driven by modern therapeutic methods. As we move into 2026, the demand for pharmaceuticals is expected to remain structurally stable, albeit with increasing cost pressures that companies must navigate.
For German pharmaceutical manufacturers, this burgeoning market represents a positive signal for investment. Currently, only a few German companies, such as Bayer, Boehringer Ingelheim, and Merck, have established a permanent presence in Morocco. However, there are various strategies for market entry that interested German firms can pursue. These include exporting high-quality finished pharmaceuticals independently, collaborating with local distribution partners, or outsourcing production to established Moroccan laboratories. It is noteworthy that the current market size does not yet justify the establishment of wholly-owned production facilities by German firms.
Strategic Partnerships and Local Production Benefits
In terms of distribution, German suppliers can leverage the existing market structure by introducing innovative specialty medications, particularly in areas such as biologics, oncology, cardiometabolic therapies, and hospital products. There are also additional opportunities in the supply of active ingredients, excipients, and process-related chemicals, with the local industry remaining highly import-dependent in these sectors. The Moroccan government and its economy favor the outsourcing of production contracts to local laboratories over outright imports, which aligns with the regulatory environment that often necessitates a physical presence or local cooperation for compliance.
Manufacturers are legally mandated to ensure that domestic supply is prioritized before exporting, necessitating that pharmaceutical laboratories maintain safety stocks. This results in limited short-term export opportunities for certain product categories. However, domestic supply chains are proving to be stable and reliable. Additionally, by outsourcing production to local laboratories, German companies can benefit from reduced regulatory hurdles, as these facilities are equipped with the necessary licenses and permits for local manufacture and sales. Production quantities exceeding local demand can be more easily exported to other African nations through established local partners, who typically have the appropriate distribution channels for southern markets.
Morocco has evolved into not only a significant regional production hub but also an export center, facilitating shipments to both Europe and Africa. Given the fragmented regulatory landscape in Sub-Saharan Africa, with varying approval processes, it is advisable for German pharmaceutical companies to leverage the experience of Moroccan partners when entering these markets. This strategic collaboration can save invaluable time and reduce unnecessary costs.
In conclusion, the Moroccan pharmaceutical industry is well-developed compared to its regional peers, with 56 industrial manufacturing entities covering a broad spectrum of dosage forms and collaborating with international partners. Leading manufacturers like Sothema and Cooper Pharma are already engaged in tailored contract manufacturing processes and active export strategies. As the regulatory landscape undergoes transformation with the establishment of the AMMPS authority, the unification and digitization of procedures are set to enhance product quality and compliance while introducing new obligations in areas such as auditing and batch documentation.
As reported by gtai.de.
